Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.79 |
| ▸ | XDH | P47989 | 6/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CDC7 | O00311 | 2/20 | 0.53 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822785 | 0.96 | GSK3B (0.84) | GSK3BXDHGAAMAPTHPGD | |
| SCHEMBL28132422 | 0.90 | GSK3B (0.70) | GSK3BXDHGAAMAPTHPGD | |
| SCHEMBL5381549 | 0.88 | GSK3B (1.00) | GSK3BXDHGAAMAPTHPGD | |
| SCHEMBL23054678 | 0.86 | GSK3B (0.65) | GSK3BXDHGAAMAPTHPGD | |
| SCHEMBL28133262 | 0.86 | GSK3B (0.65) | GSK3BXDHGAAMAPTHPGD | |
| SCHEMBL7228356 | 0.86 | GSK3B (0.69) | GSK3BXDHHPGDPDE2A | |
| SCHEMBL5384455 | 0.83 | GSK3B (0.75) | GSK3BXDHGAAMAPTHPGD | |
| SCHEMBL7235282 | 0.83 | GSK3B (0.60) | GSK3BXDHGAAMAPTHPGD | |
| SCHEMBL14935666 | 0.82 | GSK3B (0.73) | GSK3BXDHGAAMAPTHPGD | |
| SCHEMBL6969615 | 0.81 | XDH (0.66) | GSK3BXDHHPGDSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226066-A1 | CARDIOPROTECTION BY AUTOPHAGY INDUCTION AND METABOLIC REPROGRAMMING | Universite Paris-Saclay (FR) | 2024-07-11 | — | — | US | disclosed |
| US-20240226066-A1 | CARDIOPROTECTION BY AUTOPHAGY INDUCTION AND METABOLIC REPROGRAMMING | Universite Paris-Saclay (FR) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226066-A1 | CARDIOPROTECTION BY AUTOPHAGY INDUCTION AND METABOLIC REPROGRAMMING | BECN1, SQSTM1, TFEB | GSK3B 917/4885XDH 2475/4885GAA 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.